CNS

Leqembi (lecanemab)

Eisai / Biogen

Anti-amyloid antibody. FDA approved. AHEAD 3-45 Phase 3 prevention trial ongoing in pre-symptomatic AD. Subcutaneous maintenance dosing approved Aug 2025. Rolling sBLA for induction dosing initiated.

Alzheimer's DiseasePreclinical AD

Linked Studies

NCT04468659PrimaryACTIVE_NOT_RECRUITINGPHASE3

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Preclinical Alzheimer's DiseaseEarly Preclinical Alzheimer's DiseaseUpdated Mar 2026

Loading comments…

Also Known As

Other names

lecanemab

Search all trials →Request coverage update